Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development.
Diet-induced changes in the activities of bacterial enzymes are known to play a role in colon cancer development. Resveratrol has been implicated as a protective agent in carcinogenesis. In the present study, the effect of resveratrol on the activities of faecal and colonic biotransforming enzymes such as beta-glucuronidase, beta-glucosidase, beta-galactosidase, mucinase, nitroreductase and faecal sulfatase activity was assessed. The total number of aberrant crypt foci and their distribution in the proximal, medial and distal colon were observed in 1,2-dimethylhydrazine (DMH)-induced rats (group 3) and other treatment groups (groups 4-6). DMH (0.02 g/kg body weight) was given subcutaneously once a week for 15 consecutive weeks, and the experiment was terminated at 30 weeks. DMH-treated rats showed elevated levels of cancer-associated bacterial enzyme activities, whereas on resveratrol supplementation in three different regimens, rats showed lowered activities. Resveratrol supplementation throughout the experimental period (group 6) exerted a more pronounced effect (P < 0.01) by modulating the development of aberrant crypt foci and the activities of bacterial enzymes than did the other treatment regimens (groups 4 and 5). Thus, the present results demonstrate the inhibitory effect of resveratrol on DMH-induced colon carcinogenesis in rats.
Sengottuvelan
Murugan
M
Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar - 608 002, Tamilnadu, India.
Nalini
Namasivayam
N
D019813:1,2-Dimethylhydrazine; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001419:Bacteria / Q000201:enzymology; D002273:Carcinogens; D003106:Colon / Q000201:enzymology / Q000382:microbiology; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D019587:Dietary Supplements; D004195:Disease Models, Animal; D005243:Feces / Q000201:enzymology; D006026:Glycoside Hydrolases / Q000378:metabolism; D007413:Intestinal Mucosa / Q000201:enzymology; D008297:Male; D009601:Nitroreductases / Q000378:metabolism; D011133:Polysaccharide-Lyases / Q000378:metabolism; D011230:Precancerous Conditions / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D013429:Sulfatases / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D002273:Carcinogens; D013267:Stilbenes; D009601:Nitroreductases; D013429:Sulfatases; D006026:Glycoside Hydrolases; D011133:Polysaccharide-Lyases; C100002:hyaluronate lyase; D019813:1,2-Dimethylhydrazine; D000077185:Resveratrol